
Overview
Novisc Pharma is a medical devices company offering hyaluronic acid products for orthopedic use, including Hya-Joint 1% and Hya-Joint Plus 2%, as well as Chondrum+ and nitrile gloves. Hya-Joint Plus is a concentrated 2% hyaluronic acid gel developed for single-injection treatment, while Hya-Joint is a 1% formulation. The products are presented as supporting joint lubrication, flexibility and mobility.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $2,020 |
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 383 days for 2022).
- 202529/07/2026
- 202415/07/2025
- 202329/11/2024
- 202201/08/2024
- 202113/10/2022
- 202030/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Medical devices
- Hyaluronic acid
- Joint injection preparations
- Nitrile gloves
Websites
- hya-joint.comNovisc Pharma (Poland)WordPress 4.0Apache
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Konrad Antoni Szostek age 39 | 380 | $10,264.72 | 95% |
Others | 20 | $540.25 | 5% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2013-02-06.
34 1050 1025 1000 0091 3214 5666
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $68,083.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 18, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,989$1,989 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $193$193 | Prezes Zakładu Ubezpieczeń Społecznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Aqvitox Polska sp. z o.o. | $3,504,497.00 | aqvitox.pl | ||
| Fidia Pharma Polska sp. z o.o. | $2,337,177.58 | fidiapharma.pl | ||
| NEWU sp. z o.o. | $1,962,782.11 | newu.pl | ||
| Atradis Polska sp. z o.o. | $1,284,064.17 | atradis.pl | ||
| Aptissen Polska sp. z o.o. | $1,246,592.59 | aptissen.com | ||
| Komak-Med sp. z o.o. + limited partnership | $1,162,351.31 | komak.pl | ||
| Medical Expert Poland sp. z o.o. | $1,126,528.51 | intermedexp.pl | ||
| JJH Medical Bartosz Hiczkiewicz sp. k. | $1,076,466.09 | jjhmedical.com | ||
| Capeypharma sp. z o.o. | $723,168.08 | capeypharma.com | ||
| TNS Silesia sp. z o.o. | $540,294.95 | hialupharm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2015-07-20 | PKD change (Removed: 10 codes; Added: 6 codes) | |
| 2012-12-13 | Entered in the register |
FAQ
Last updated: 2026-09-19